Guillain-barré Syndrome
📧 Sign up to get email alerts when something new happens for Guillain-barré Syndrome.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-05-28EMA Authorised: Privigen (human normal immunoglobulin (IVIg)) — CSL Behring GmbH
Privigen (human normal immunoglobulin IVIg) has been authorised by the EMA for multiple indications. The listed therapeutic areas include id…
-
EMA approval · 2025-05-16EMA Authorised: Deqsiga (human normal immunoglobulin) — Takeda Manufacturing Austria AG
EMA authorised Deqsiga, a human normal immunoglobulin product from Takeda Manufacturing Austria AG, for several immunologic and neuropathic …
-
EMA approval · 2024-01-11EMA Authorised: Flebogamma DIF (previously Flebogammadif) (human normal immunoglobulin) — Instituto Grifols S.A.
EMA authorises Flebogamma DIF (human normal immunoglobulin) for multiple immunological indications including mucocutaneous lymph node syndro…
-
EMA approval · 2022-06-27EMA Authorised: Kiovig (human normal immunoglobulin (IVIg)) — Takeda Manufacturing Austria AG
Kiovig (human normal immunoglobulin IVIg) has been authorised by EMA for multiple indications including immune thrombocytopenic purpura, bon…